March 28, 2019

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Intimation of Appointment of Ms. Sona Saira Ramasastry (DIN-0008398547) as an Additional Director - Independent Director

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), we are pleased to inform that on recommendation of Nomination & Remuneration Committee, the Board has appointed Ms. Saira as an Additional Director to hold office as an Independent Director of the Company for a term of Five years with effect from 1st April, 2019, not liable to retire by rotation, subject to the approval of the shareholders at the ensuing General Meeting.

Ms. Saira is not debarred from holding the office of director by virtue of any order passed by SEBI or any other authority.

Accordingly, please find enclosed the requisite information as required under SEBI Circular dated 9th September, 2015 content of which is self-explanatory.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Particulars</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Name of Director</td>
<td>Ms. Sona Saira Ramas�� (DIN-0008398547)</td>
</tr>
<tr>
<td>2.</td>
<td>Reason for change viz. appointment, resignation, removal, death or otherwise</td>
<td>Appointment</td>
</tr>
<tr>
<td>3.</td>
<td>Date of appointment &amp; term of appointment</td>
<td>Ms. Saira has been appointed as an Additional Director - Independent Director of the Company for a term of five years with effect from 1st April, 2019, not liable to retire by rotation, subject to the approval of the shareholders at the ensuing General Meeting.</td>
</tr>
<tr>
<td>4.</td>
<td>Brief Profile (in case of appointment)</td>
<td>Ms. Saira has over 20 years of experiences in life sciences industry successfully building companies as an advisor, board member and operational executive. Ms. Saira is the Founder &amp; Managing Director of Life Sciences Advisory (since 2009) and also associated with European Prevention of Alzheimer’s Dementia (EPAD) as Head, Business &amp; Sustainability (since 2015) where she is currently leading processes to create $50 million public private consortium focused on Alzheimer’s Dementia (AD) prevention. She is also working as Strategic Advisor with G8 Health Initiatives (since 2013) and is the Co-Founder and President of For Life Institute (since 2017). Ms. Saira’s past experiences include serving as Head, Emerging Biotechnology Investment Banking with Merrill Lynch &amp; Co. and as Healthcare M&amp;A Analyst at Wasserstein Perella. Ms. Saira also serves on the Board of Sangamo Biosciences, Inc., PTI Therapeutics and Innovate Biopharmaceuticals, Inc., each a publicly-held company. She also serves as Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and Advisory Council for University of Cambridge.</td>
</tr>
</tbody>
</table>
Ms. Saira’s accomplishments include being named as top life sciences advisor by Acquisition International and CorporateLiveWire

Ms. Saira is B.A. in Economics with Honors and an M.S. in Management Science and Engineering from Stanford University. She also holds M. Phil. in Finance and Management Studies from the University of Cambridge.

| 5. | Disclosure of relationships between directors (in case of appointment of a director) | Ms. Saira is not related to any Board Member of the Company. |